These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8999136)

  • 1. [In vitro anti-MAC activities of new quinolones in focus (1)].
    Tsuyuguchi K
    Kekkaku; 1996 Sep; 71(9):536-7. PubMed ID: 8999136
    [No Abstract]   [Full Text] [Related]  

  • 2. [In vitro anti-MAC activities of new quinolones in focus (2)].
    Kawahara S; Eirei J
    Kekkaku; 1996 Sep; 71(9):537-9. PubMed ID: 8999137
    [No Abstract]   [Full Text] [Related]  

  • 3. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1996 Sep; 71(9):531-5. PubMed ID: 8999135
    [No Abstract]   [Full Text] [Related]  

  • 4. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of multiple drug-resistance between Mycobacterium avium complex and Mycobacterium fortuitum and Mycobacterium chelonae].
    Tsukamura M
    Kekkaku; 1988 Aug; 63(8):563-8. PubMed ID: 3184587
    [No Abstract]   [Full Text] [Related]  

  • 6. N1-phenyl substituted 4-quinolones of tuberculostatic activity.
    Holzgrabe U; Steinert M
    Pharmazie; 2001 Nov; 56(11):850-1. PubMed ID: 11817167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity.
    Kamal A; Reddy KS; Ahmed SK; Khan MN; Sinha RK; Yadav JS; Arora SK
    Bioorg Med Chem; 2006 Feb; 14(3):650-8. PubMed ID: 16203154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of microplate Alamar blue assay for drug susceptibility testing of Mycobacterium avium complex isolates.
    Vanitha JD; Paramasivan CN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):179-82. PubMed ID: 15246507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
    Bermudez LE; Kolonoski P; Petrofsky M; Wu M; Inderlied CB; Young LS
    J Infect Dis; 2003 Jun; 187(12):1977-80. PubMed ID: 12792877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
    Foroumadi A; Soltani F; Moshafi MH
    Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies.
    Klopman G; Wang S; Jacobs MR; Ellner JJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1807-15. PubMed ID: 8239588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media.
    Kamala T; Herbert D; Venkatesan P; Paramasivan CN
    Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):375-8. PubMed ID: 9401493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.
    Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitubercular agents. Part 1: synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents.
    Kamal A; Hari Babu A; Venkata Ramana A; Sinha R; Yadav JS; Arora SK
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1923-6. PubMed ID: 15780634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
    Cai S; Sato K; Shimizu T; Yamabe S; Hiraki M; Sano C; Tomioka H
    J Antimicrob Chemother; 2006 Jan; 57(1):85-93. PubMed ID: 16303883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro antimycobacterial activities of a new quinolone, balofloxacin].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.
    Tan CK; Lai CC; Liao CH; Chou CH; Hsu HL; Huang YT; Hsueh PR
    J Antimicrob Chemother; 2009 Aug; 64(2):428-9. PubMed ID: 19454523
    [No Abstract]   [Full Text] [Related]  

  • 20. A new TB drug by 2010--or sooner?
    Crabb C
    Bull World Health Organ; 2002; 80(6):518-9. PubMed ID: 12132015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.